within Pharmacolibrary.Drugs.ATC.J;

model J01DI54
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0072,
    k12             = 9.4,
    k21             = 9.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DI54</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceftolozane and tazobactam is a combination of a cephalosporin antibiotic (ceftolozane) and a β-lactamase inhibitor (tazobactam). It is used for the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis. The combination is approved for clinical use and has activity against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained in healthy adult subjects, both male and female, age range approximately 18–50 years, following intravenous infusion.</p><h4>References</h4><ol><li><p>van Duin, D, &amp; Bonomo, RA (2016). Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 63(2) 234–241. DOI:<a href=\"https://doi.org/10.1093/cid/ciw243\">10.1093/cid/ciw243</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27098166/\">https://pubmed.ncbi.nlm.nih.gov/27098166</a></p></li><li><p>Nicolau, DP, et al., &amp; Rizk, ML (2021). Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International journal of antimicrobial agents</i> 57(4) 106299–None. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2021.106299\">10.1016/j.ijantimicag.2021.106299</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33567333/\">https://pubmed.ncbi.nlm.nih.gov/33567333</a></p></li><li><p>Al Jalali, V, et al., &amp; Zeitlinger, M (2021). Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study. <i>The Journal of antimicrobial chemotherapy</i> 76(9) 2342–2351. DOI:<a href=\"https://doi.org/10.1093/jac/dkab166\">10.1093/jac/dkab166</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34050650/\">https://pubmed.ncbi.nlm.nih.gov/34050650</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DI54;
